First-of-its-kind Narcolepsy Drug Hailed As 'Transformative'

The medication, which targets a different pathway in the brain than existing treatments, has shown in clinical trials to significantly reduce excessive daytime sleepiness and cataplexy episodes. Researchers say the drug could change the standard of care for the estimated three million people worldwide affected by narcolepsy. The approval marks a major step forward in addressing a chronic neurological disorder that has long been underdiagnosed and undertreated.